Feature | Contrast Media Injectors | March 07, 2018 | Grand View Research Inc.

Contrast Media Injectors A $1.4 B Market by 2025

This article originally ran as the Contrast Media Injectors chart introduction in the March 2018 issue. The chart can be viewed here.

OptiStar Elite injector

The global contrast media injectors market is expected to reach $1.4 billion by 2025, growing at a compound annual growth rate (CAGR) of 5.8 percent, according to a new report by Grand View Research, Inc., a research firm based in San Francisco. Rising demand for minimally invasive surgical procedures is a major factor expected to boost the market during the forecast period. These devices assist surgeons in accurate insertion of contrast agents with reduced human errors, thus increasing the accuracy and efficiency of surgical procedures. They play a crucial role in intra-operative computed tomography (iCT), intra-operative magnetic resonance imaging (iMRI) and interventional cardiology. Availability of advanced injector systems for diagnosis and intra-operative imaging has boosted adoption of these systems.

Technological advancements, such as automated contrast media injectors and double-head injectors, are also among major factors supporting the growth of the market. Automated contrast media injectors provide improved patient safety, accuracy and enhance image quality. Also, double-head injectors allow a large and rapid initial bolus of contrast, which is required in several imaging procedures.

Minimally invasive surgical procedures provide various advantages, such as smaller incisions, rapid wound healing, shorter hospital stays, less pain and minor surgical wounds. Minimally invasive surgical procedures with contrast media injectors deliver high-quality real-time imaging of the surgical site, and ensure that surgeons are treating the appropriate area. Thus, adoption of these products for minimally invasive surgeries is rising gradually and expected to fuel growth.

Increase in prevalence of several chronic diseases, such as cancer, as well as cardiac, neurological and orthopedic diseases is expected to boost the market. According to the American Cancer Society (ACS), an estimated 1.7 million new cancer cases were diagnosed in 2017 in the U.S. The ACS also stated that 28.4 million adults were diagnosed with heart disease in 2015. Thus, there is growing demand for advanced products for diagnosis and treatment of chronic diseases, which is projected to drive growth.

 

CT Injector Insights

In 2016, the CT injector systems segment was the largest revenue-generating segment of the market due to widespread application of these systems in cancer surgery, neurosurgery, cardiovascular surgery and spinal procedures. In addition, high adoption of minimally invasive surgeries is expected to boost the market.

The rising prevalence of chronic diseases, including cancer, neurological disorders and arthritis, is expected to propel demand for this product segment. According to the World Health Organization (WHO), cancer is the second largest cause of death, and around 14 million new cases of cancer were diagnosed worldwide in 2012.

The MRI injector systems segment is expected to exhibit the highest growth over the study period owing to technological advancements such as 3-D isotropic imaging, high efficiency in tumor detection, higher quality visualization and exquisite quality imaging.

 

Type Insights

In 2016, the single-head injectors segment accounted for the largest revenue share of the market because it is most widely used for angiography, CT and MRI. In addition, the low price of these products as compared to other systems is expected to drive demand in emerging economies, such as China, India and Brazil. The launch of new products is expected to boost this segment.

The syringeless injectors segment is expected to grow with the highest CAGR during the forecast period owing to its advantages, such as user-friendliness, high efficiency and minimum wastage of contrast media. Several leading players are focusing on development and launching of syringeless injectors, which is projected to drive the growth of the segment.

Availability of well-established healthcare infrastructure and high healthcare expenditure in developed countries, including the U.S., Japan, France, Germany and the U.K., is expected to boost the market. According to the Centers for Medicare and Medicaid Services, U.S. healthcare expenditure was around $3.2 trillion in 2015 and accounted for approximately 17.8 percent of the gross domestic product. These factors are expected to support market growth.

 

Application Insights

The radiology segment held the largest share in the market because it is primarily for diagnosis of various diseases including heart conditions, breast cancer, colon cancer, broken bones, gastrointestinal conditions and blood clots. In addition, this segment is projected to grow at a lucrative rate owing to rise in demand for noninvasive medical imaging techniques.

The U.S., Japan, Germany, U.K. and France are estimated to account for the maximum usage of contrast media injectors. Rise in the burden of several chronic diseases, growing investments by governments to improve healthcare infrastructure and availability of expert radiologists in these countries is projected to contribute toward growth. 

 

Grand View Research is a U.S.-based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports and consulting services. Grand View Research database is used by the world’s renowned academic institutions and Fortune 500 companies to understand global and regional business environment.

Related Content

the Contrast Media Injectors Market is estimated to be USD 1.3 billion in 2020 and  projected to reach $1.9B by 2025, at a CAGR of 7.4% between 2020 and 2025

Getty Images

News | Contrast Media Injectors | September 02, 2020
September 2, 2020 — According to the new market research report "...
The first and only FDA-approved gadolinium-based contrast agent for multi-patient dosing with an FDA-cleared Transfer Spike in the MR suite
News | Contrast Media | August 14, 2020
August 14, 2020 — The U.S.
The Global Contrast Injectors Market will grow by $613.47M during 2020-2024, according to Technavio
News | Contrast Media Injectors | June 17, 2020
June 17, 2020 — Technavio has been monitoring the ...
The FDA has approved Lilly’s TAUVID (flortaucipir F 18 injection), a radioactive diagnostic agent, for PET imaging of the brain to estimate the density and distribution of aggregated tau neurofibrillary tangles (NFTs) in adult patients with cognitive impairment who are being evaluated for Alzheimer’s disease

Getty Images

News | Contrast Media | June 01, 2020
June 1, 2020 — TAUVID, a radioactive diagnostic agent, has been approved by the FDA for...
Researchers from Tokyo Metropolitan University have surveyed the amount of gadolinium found in river water in Tokyo. Gadolinium is contained in contrast agents given to patients undergoing medical magnetic resonance imaging (MRI) scans, and it has been shown in labs to become toxic when exposed to ultraviolet rays. The researchers found significantly elevated levels, particularly near water treatment plants, highlighting the need for new public policy and removal technologies as MRI become even more commonp

Samples were taken along rivers around Tokyo. Measurements of rare earth element quantities indicate a clearly elevated amount of gadolinium compared to that in natural shale. Graphics courtesy of Tokyo Metropolitan University

News | Magnetic Resonance Imaging (MRI) | May 26, 2020
May 26, 2020 — Researchers from Tokyo Metropolitan...
Gadolinium-based contrast agents

UT Dallas faculty members who collaborated with Dr. Jeremiah Gassensmith (center, back), associate professor of chemistry and biochemistry, include Dr. Lloyd Lumata (left, back), assistant professor of physics, and Dr. Steven Nielsen, associate professor of chemistry. Chemistry graduate students in Gassensmith’s lab include (from left, front) Oliva Brohlin, Arezoo Shahrivarkevishahi and Laurel Hagge.

News | Contrast Media | February 06, 2020
February 6, 2020 — University of Texas at Dallas researchers